Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation

作者: Jing Gao , Yan-Yan Li , Ping-Nai Sun , Lin Shen , None

DOI: 10.3748/WJG.V16.I38.4858

关键词:

摘要: AIM: To compare the differences between dideoxy sequencing/KRAS StripAssay/pyrosequencing for detection of KRAS mutation in Chinese colorectal cancer (CRC) patients. METHODS: Formalin-fixed, paraffin-embedded (FFPE) samples with tumor cells ≥ 50% were collected from 100 CRC patients at Beijing Cancer Hospital. After extraction genome DNA FFPE samples, fragments contained codons 12 and 13 exon 2 amplified by polymerase chain reaction analyzed sequencing, StripAssay pyrosequencing. In addition, sensitivities 3 methods compared on serial dilutions (contents mutant DNA: 100%, 50%, 20%, 15%, 10%, 5%, 1%, 0%) A549 cell line (carrying codon Gly>Ser mutation) into wild-type (human normal intestinal mucosa). The results pyrosequencing Chromas Software, Collector PyroMarkTM Q24 system, respectively. RESULTS: Among patients, mutations identified 34%, 37% pyrosequencing, respectively. sensitivity was highest (1%), followed (5%), sequencing lowest (15%). Six different types found this study main Gly12Asp (GGT>GAT), Gly12Val (GGT>GTT) Gly13Asp (GGC>GAC). Thirty-three to have methods, a total 8 had conflicting methods: 4 not detected pyrosequencing; StripAssay; 1 confirmed StripAssay. these discordant results, consistent either or which indicated that accuracy high. CONCLUSION: Taking worldwide view reports our remains most popular method because its low cost high accuracy.

参考文章(18)
C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000
Mohamed Hebbar, Agne`s Wacrenier, Christophe Desauw, Olivier Romano, Ste??phane Cattan, Jean-Pierre Triboulet, Francois-Rene?? Pruvot, Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anti-Cancer Drugs. ,vol. 17, pp. 855- 857 ,(2006) , 10.1097/01.CAD.0000217425.44584.9F
Shuji Ogino, Takako Kawasaki, Mohan Brahmandam, Liying Yan, Mami Cantor, Chungdak Namgyal, Mari Mino-Kenudson, Gregory Y. Lauwers, Massimo Loda, Charles S. Fuchs, Sensitive Sequencing Method for KRAS Mutation Detection by Pyrosequencing The Journal of Molecular Diagnostics. ,vol. 7, pp. 413- 421 ,(2005) , 10.1016/S1525-1578(10)60571-5
Angela Poehlmann, Doerthe Kuester, Frank Meyer, Hans Lippert, Albert Roessner, Regine Schneider-Stock, K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathology Research and Practice. ,vol. 203, pp. 489- 497 ,(2007) , 10.1016/J.PRP.2007.06.001
J Breivik, GI Meling, A Spurkland, TO Rognum, G Gaudernack, K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. British Journal of Cancer. ,vol. 69, pp. 367- 371 ,(1994) , 10.1038/BJC.1994.67
Chi-Ming Wu, Reiping Tang, Jeng-Yi Wang, Chung-Rong Changchien, Ling-Ling Hsieh, Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. Cancer Genetics and Cytogenetics. ,vol. 158, pp. 55- 60 ,(2005) , 10.1016/J.CANCERGENCYTO.2004.08.030
Bert Vogelstein, Eric R Fearon, Stanley R Hamilton, Scott E Kern, Ann C Preisinger, Mark Leppert, Yusuke Nakamura, Ray White, Alida MM Smits, Johannes L Bos, Genetic alterations during colorectal-tumor development. The New England Journal of Medicine. ,vol. 319, pp. 525- 532 ,(1988) , 10.1056/NEJM198809013190901
Derek J. Jonker, Chris J. O'Callaghan, Christos S. Karapetis, John R. Zalcberg, Dongsheng Tu, Heather-Jane Au, Scott R. Berry, Marianne Krahn, Timothy Price, R. John Simes, Niall C. Tebbutt, Guy van Hazel, Rafal Wierzbicki, Christiane Langer, Malcolm J. Moore, Cetuximab for the Treatment of Colorectal Cancer The New England Journal of Medicine. ,vol. 357, pp. 2040- 2048 ,(2007) , 10.1056/NEJMOA071834
Michael Huncharek, Joshua Muscat, Jean-Francois Geschwind, K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis. ,vol. 20, pp. 1507- 1510 ,(1999) , 10.1093/CARCIN/20.8.1507